ProCE Banner Activity

TROPiCS-02: Final OS Analysis of the Phase III Trial of Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- Advanced Breast Cancer

Conference Coverage
Slideset

Exploratory extended efficacy analysis of the TROPiCS-02 trial demonstrated durable efficacy with sacituzumab govitecan compared with physician’s choice of capecitabine, vinorelbine, gemcitabine, or eribulin in patients with pretreated ET-resistant HR+/HER2- MBC.

Released: June 13, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.

AstraZeneca

Daiichi Sankyo

Gilead

Merck Sharp & Dohme Corp.